Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/ijms21114119
Keywords
1301 human lymphoblastic leukemia; carbosilane dendrimer; ruthenium; drug delivery; cytotoxicity
Funding
- Project EUROPARTNER of Polish National Agency for Academic Exchange (NAWA)
- PI-SK 2019-2020 bilateral project [PPN/BIL/2018/1/00150]
- project NanoTENDO - National Science Centre, Poland under the M-ERA.NET 2 of Horizon 2020 programme [685451]
- MINECO [CTQ2017-86224-P]
- consortiums IMMUNOTHERCAN-CM [B2017/BMD-3733]
- NANODENDMED II-CM [B2017/BMD-3703]
- Junta de Comunidades de Castilla-La Mancha (JCCM) [SBPLY/17/180501/000358]
- VI National R&D&I Plan 2008-2011, IniciativaIngenio 2010, Consolider Program, CIBER Actions
- Instituto de Salud Carlos III
- European Regional Development Fund
Ask authors/readers for more resources
Ruthenium atoms located in the surfaces of carbosilane dendrimers markedly increase their anti-tumor properties. Carbosilane dendrimers have been widely studied as carriers of drugs and genes owing to such characteristic features as monodispersity, stability, and multivalence. The presence of ruthenium in the dendrimer structure enhances their successful use in anti-cancer therapy. In this paper, the activity of dendrimers of generation 1 and 2 against 1301 cells was evaluated using Transmission Electron Microscopy, comet assay and Real Time PCR techniques. Additionally, the level of reactive oxygen species (ROS) and changes of mitochondrial potential values were assessed. The results of the present study show that ruthenium dendrimers significantly decrease the viability of leukemia cells (1301) but show low toxicity to non-cancer cells (peripheral blood mononuclear cells-PBMCs). The in vitro test results indicate that the dendrimers injure the 1301 leukemia cells via the apoptosis pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available